Table 2.

Individual patient vignettes

1- Improved creatinine clearance/stable spirometry/BOS 2/C/B HFpEF/(–) DSA

2- Slow decrement creatinine clearance/stable spirometry/BOS 3/(–) DSA

3- Improved creatinine clearance/progressive R-CLAD → D/C BSX (12 months)/(–) DSA

4- Stable creatinine clearance (12 months)/progressive BOS 1 → 2/C/B HFpEF/Pneumonia (Deceased)

5- Improved creatinine clearance/stable R-CLAD (7 months)/(+)de novo HLA class II DSA/C/B viral PNA → D/C BSX after 7 months → IVIG + rituximab

6- Improved creatinine clearance/stable R-CLAD/(–) DSA

7- Stable creatinine clearance (16 months) → ESRD + HD/C/B recurrent CHF + HFpEF + possible AR → D/C BSX → rabbit ATG with stable spirometry (BOS 0)/(–) DSA

8- Stable creatinine clearance (4 months) C/B AKI + CKD → HD/stable R-CLAD → C/B sepsis + acute + chronic respiratory failure at 6 months (Deceased)/(–) DSA

9- Improved creatinine clearance/C/B Parainfluenza-II PNA + BOS 3 → (Deceased) after 8 months/weak (+) de novo HLA class II DSA

ATG: Anti-thymocyte globulin; HFpEF: Heart failure with preserved ejection fraction; DSA: Donor-specific HLA antibodies; BOS: Bronchiolitis obliterans syndrome; RAS: Restrictive allograft syndrome; AR: Acute rejection; AKI: Acute kidney injury; ESRD: End-stage renal disease